Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
76 hedge funds and large institutions have $246M invested in Syros Pharmaceuticals, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 25 reducing their positions, and 8 closing their positions.
66% more call options, than puts
Call options by funds: $464K | Put options by funds: $279K
22% more capital inflows, than outflows
Capital inflows: $13.4M | Capital outflows: $11M
0% more funds holding
Funds holding: 76 → 76 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
0% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 25
1.43% less ownership
Funds ownership: 62.71% → 61.28% (-1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARK Investment Management
St. Petersburg,
Florida
|
+$4.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.87M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.74M |
| 4 |
Wedge Capital Management
Charlotte,
North Carolina
|
+$712K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$505K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.35M |
| 2 |
Renaissance Technologies
New York
|
-$1.58M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.55M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$985K |
| 5 |
Two Sigma Investments
New York
|
-$696K |
SYRS Hedge Fund Activity: Q3 2018 in Review
76 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q3 2018, worth a combined $246M — up 18% from $209M a quarter earlier.
Fund positioning in SYRS was balanced in Q3 2018: 8 funds opened new positions, 8 closed out, 25 added to existing stakes and 25 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $4.9M. The largest seller was Millennium Management, cutting an estimated $2.35M.
- 76 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $246M of Syros Pharmaceuticals, Inc. Common Stock stock for Q3 2018, up 18% quarter-over-quarter.
- 8 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q3 2018 and 8 closed out, a net change of 0 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q3 2018 was ARK Investment Management, an estimated $4.9M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q3 2018 was Millennium Management, an estimated $2.35M sold.
Based on aggregated 13F filings for Q3 2018.